2023
1483. Real-time Creation of HCV Treatment Cascades in Clinics to Improve HCV Treatment Rates Among Patients with HIV/HCV Co-infection
Wegener M, Brooks R, Nichols L, Villanueva M. 1483. Real-time Creation of HCV Treatment Cascades in Clinics to Improve HCV Treatment Rates Among Patients with HIV/HCV Co-infection. Open Forum Infectious Diseases 2023, 10: ofad500.1319. PMCID: PMC10677588, DOI: 10.1093/ofid/ofad500.1319.Peer-Reviewed Original ResearchHIV/HCVHCV treatmentHealth departmentsHIV/HCV Co-infectionSurveillance dataHCV Co-InfectionHCV PCR testingHCV surveillance dataHCV treatment cascadeHCV treatment ratesClinical care dataCounty Health DepartmentHCV careRyan WhiteSVR ratesHCV diagnosisTreatment cascadeTreatment initiationCo-InfectionHCV surveillanceTreatment eligibilityViral clearanceClinic levelCase conferencingMedical records2510. Adapting the CDC HCV viral clearance cascade methodology for persons with HIV (PWH) and HCV co-infection in 5 Health Department Jurisdictions in the US
Wegener M, Brooks R, Nichols L, Villanueva M. 2510. Adapting the CDC HCV viral clearance cascade methodology for persons with HIV (PWH) and HCV co-infection in 5 Health Department Jurisdictions in the US. Open Forum Infectious Diseases 2023, 10: ofad500.2128. PMCID: PMC10678948, DOI: 10.1093/ofid/ofad500.2128.Peer-Reviewed Original ResearchHCV surveillance dataPrevalent HIVRecent HCVViral clearanceViral testingHealth jurisdictionsInitial infectionHIV transmission risk factorsHIV/HCV coinfectionUndetectable HIV viral loadSurveillance dataHCV cure ratesHCV test resultsHCV viral clearanceHealth department jurisdictionsHIV viral loadHIV/HCVCo-infected populationTransmission risk factorsCoinfected populationHCV cascadeHCV coinfectionHCV microeliminationHCV clearanceHIV careChallenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessions
2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptake